Literature DB >> 12475899

Epidermal growth factor receptor trans-activation mediates the tonic and fibrogenic effects of endothelin in the aortic wall of transgenic mice.

Martin Flamant1, Pierre-Louis Tharaux, Sandrine Placier, Daniel Henrion, Tom Coffman, Christos Chatziantoniou, Jean-Claude Dussaule.   

Abstract

Vascular remodeling and rearrangement of the extracellular matrix formation are among the major adaptive mechanisms in response to a chronic blood pressure increase. Vasoactive peptides, such as endothelin, participate in hypertension-associated vascular fibrosis by stimulating collagen I formation and increasing contractility of arterial wall. In the present study, we tested the hypothesis that activation of the epidermal growth factor (EGF) receptor pathway mediates these events. Experiments were performed in transgenic mice harboring the luciferase gene under the control of the collagen I-alpha2 chain promoter. Endothelin induced a rapid phosphorylation of the mitogen-activated protein kinase (MAPK)/ERK and increased collagen I gene activity in freshly isolated aortas. This effect of endothelin was totally inhibited by an endothelin receptor antagonist, an EGF receptor phosphorylation inhibitor, and a blocker of the MAPK/ERK cascade. In parallel experiments, inhibition of EGF receptor phosphorylation decreased the endothelin-induced pressor effect in isolated aortic rings and in anesthetized animals in vivo. In addition, the endothelin-induced increase of blood pressure was blunted in the waved-2 mice, a strain expressing functionally impaired EGF receptors. Our results provide the first evidence that the EGF receptor mediates at least two of the major actions of endothelin in the vascular tissue: contractility and fibrogenesis.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12475899     DOI: 10.1096/fj.02-0115fje

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  18 in total

1.  Genetic or pharmacologic blockade of EGFR inhibits renal fibrosis.

Authors:  Na Liu; Jian-Kan Guo; Maoyin Pang; Evelyn Tolbert; Murugavel Ponnusamy; Rujun Gong; George Bayliss; Lance D Dworkin; Haidong Yan; Shougang Zhuang
Journal:  J Am Soc Nephrol       Date:  2012-02-23       Impact factor: 10.121

2.  Suramin inhibits renal fibrosis in chronic kidney disease.

Authors:  Na Liu; Evelyn Tolbert; Maoyin Pang; Murugavel Ponnusamy; Haidong Yan; Shougang Zhuang
Journal:  J Am Soc Nephrol       Date:  2011-05-26       Impact factor: 10.121

Review 3.  The roles of integrins in mediating the effects of mechanical force and growth factors on blood vessels in hypertension.

Authors:  Jun-Tzu Chao; Michael J Davis
Journal:  Curr Hypertens Rep       Date:  2011-12       Impact factor: 5.369

4.  EGF Receptor Inhibition Alleviates Hyperuricemic Nephropathy.

Authors:  Na Liu; Li Wang; Tao Yang; Chongxiang Xiong; Liuqing Xu; Yingfeng Shi; Wenfang Bao; Y Eugene Chin; Shi-Bin Cheng; Haidong Yan; Andong Qiu; Shougang Zhuang
Journal:  J Am Soc Nephrol       Date:  2015-03-18       Impact factor: 10.121

5.  Inhibition of matrix metalloproteinase-2 improves endothelial function and prevents hypertension in insulin-resistant rats.

Authors:  P R Nagareddy; P S Rajput; H Vasudevan; B McClure; U Kumar; K M Macleod; J H McNeill
Journal:  Br J Pharmacol       Date:  2012-02       Impact factor: 8.739

6.  Differential roles of endothelin-1 in angiotensin II-induced atherosclerosis and aortic aneurysms in apolipoprotein E-null mice.

Authors:  Renée S Suen; Sarah N Rampersad; Duncan J Stewart; David W Courtman
Journal:  Am J Pathol       Date:  2011-06-29       Impact factor: 4.307

Review 7.  The role of cell plasticity in progression and reversal of renal fibrosis.

Authors:  Jean-Claude Dussaule; Dominique Guerrot; Anne-Cécile Huby; Christos Chadjichristos; Nasim Shweke; Jean-Jacques Boffa; Christos Chatziantoniou
Journal:  Int J Exp Pathol       Date:  2011-02-12       Impact factor: 1.925

Review 8.  Progression and regression in renal vascular and glomerular fibrosis.

Authors:  Christos Chatziantoniou; Jean-Jacques Boffa; Pierre-Louis Tharaux; Martin Flamant; Pierre Ronco; Jean-Claude Dussaule
Journal:  Int J Exp Pathol       Date:  2004-02       Impact factor: 1.925

9.  Actions of aldosterone in the cardiovascular system: the good, the bad, and the ugly?

Authors:  Michael Gekle; Claudia Grossmann
Journal:  Pflugers Arch       Date:  2008-11-19       Impact factor: 3.657

Review 10.  The epidermal growth factor receptor pathway in chronic kidney diseases.

Authors:  Laura R Harskamp; Ron T Gansevoort; Harry van Goor; Esther Meijer
Journal:  Nat Rev Nephrol       Date:  2016-07-04       Impact factor: 28.314

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.